Trade Geron - GERN CFD

Trading Conditions

• Type: CFD
• Spread: 0.0182
• Long position overnight funding adjustment: -0.02171%
• Short position overnight funding adjustment: -0.00052%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premium: 1%

Key Stats

• Prev. Close: 1.6159
• Open: 1.5959
• 1-Year Change: -6.07%
• Day's Range: 1.5359 - 1.5959

What is Geron (GERN)?

Geron Corporation is a biotechnology company specializing in the development of therapeutic products for cancer treatment. The company focuses on telomerase inhibition and regenerative medicine, aiming to address diseases associated with cellular aging and uncontrolled cell growth. Geron's research includes small molecule drugs and cell therapy approaches designed to target cancer stem cells and other mechanisms involved in tumor progression. The company operates within the broader biopharmaceutical industry and collaborates with academic institutions and other biotechnology firms to advance its pipeline. Geron's work contributes to the understanding of telomere biology and its implications for oncology and regenerative medicine.

Geron Stock Price Today: Live Overview

The price today is shaped by the latest trading activity, with Geron currently at $1.5641. During the session, it has moved between $1.5459 and $1.6159, showing a daily change of -4.3053%.

FAQ: Geron (GERN)

What is the current price of GERN stock?

The latest price stands at $1.5641.

Does GERN pay dividends?

Geron does not currently pay dividends.

Does GERN have a formal corporate presence or regional headquarters in the UAE?

Geron operates through partnerships and distributors in the UAE without an official regional office or subsidiary.

What is GERN best known for?

Geron is most famous for its work in developing telomerase inhibitors for cancer treatment.

What assets are typically shown together with GERN?

Commonly shown alongside GERN: New Gold Inc., CytomX Therapeutics Inc, POET Technologies Inc